LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 6 of total 6

Search options

  1. Article: Confrontation morphologique et immunophénotypique pour le diagnostic d’une tumeur gastrique rare.

    Bocciarelli, Claire / Poureau, Pierre-Guillaume / Uguen, Arnaud / Doucet, Laurent

    Annales de pathologie

    2023  Volume 44, Issue 1, Page(s) 78–81

    Title translation Morphological and immunophenotypical confrontation in the diagnosis of a rare gastric tumor.
    MeSH term(s) Humans ; Stomach Neoplasms/diagnosis
    Language French
    Publishing date 2023-08-31
    Publishing country France
    Document type Case Reports ; Journal Article
    ZDB-ID 225720-8
    ISSN 0242-6498
    ISSN 0242-6498
    DOI 10.1016/j.annpat.2023.08.001
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1652: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: Three cases of immune cholangitis related to anti-programmed cell death and programmed cell death ligand agents for the treatment of non-small cell lung cancer.

    Fouchard, Maxime / Jantzem, Helene / Quere, Gilles / Descourt, Renaud / Robinet, Gilles / Poureau, Pierre-Guillaume

    European journal of cancer (Oxford, England : 1990)

    2019  Volume 115, Page(s) 107–110

    MeSH term(s) Adenocarcinoma of Lung/drug therapy ; Adenocarcinoma of Lung/immunology ; Adenocarcinoma of Lung/secondary ; Adrenal Cortex Hormones/therapeutic use ; Antibodies, Monoclonal/adverse effects ; Antibodies, Monoclonal, Humanized/adverse effects ; Antineoplastic Agents, Immunological/adverse effects ; Carcinoma, Non-Small-Cell Lung/drug therapy ; Carcinoma, Non-Small-Cell Lung/immunology ; Carcinoma, Non-Small-Cell Lung/secondary ; Carcinoma, Squamous Cell/drug therapy ; Carcinoma, Squamous Cell/immunology ; Carcinoma, Squamous Cell/secondary ; Cholagogues and Choleretics/therapeutic use ; Cholangitis/chemically induced ; Cholangitis/diagnosis ; Cholangitis/drug therapy ; Cholangitis/immunology ; Humans ; Lung Neoplasms/drug therapy ; Lung Neoplasms/immunology ; Lung Neoplasms/pathology ; Male ; Middle Aged ; Nivolumab/adverse effects ; Treatment Outcome ; Ursodeoxycholic Acid/therapeutic use
    Chemical Substances Adrenal Cortex Hormones ; Antibodies, Monoclonal ; Antibodies, Monoclonal, Humanized ; Antineoplastic Agents, Immunological ; Cholagogues and Choleretics ; durvalumab (28X28X9OKV) ; Nivolumab (31YO63LBSN) ; Ursodeoxycholic Acid (724L30Y2QR) ; pembrolizumab (DPT0O3T46P) ; tremelimumab (QEN1X95CIX)
    Language English
    Publishing date 2019-05-24
    Publishing country England
    Document type Case Reports ; Letter
    ZDB-ID 82061-1
    ISSN 1879-0852 ; 0277-5379 ; 0959-8049 ; 0964-1947
    ISSN (online) 1879-0852
    ISSN 0277-5379 ; 0959-8049 ; 0964-1947
    DOI 10.1016/j.ejca.2019.04.022
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 456: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 583: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article ; Online: Regorafenib-avelumab combination in patients with biliary tract cancer (REGOMUNE): a single-arm, open-label, phase II trial.

    Cousin, Sophie / Cantarel, Coralie / Guegan, Jean-Philippe / Mazard, Thibault / Gomez-Roca, Carlos / Metges, Jean-Philippe / Bellera, Carine / Adenis, Antoine / Korakis, Iphigenie / Poureau, Pierre-Guillaume / Bourcier, Kevin / Toulmonde, Maud / Kind, Michèle / Rey, Christophe / Auzanneau, Céline / Bessede, Alban / Soubeyran, Isabelle / Italiano, Antoine

    European journal of cancer (Oxford, England : 1990)

    2022  Volume 162, Page(s) 161–169

    Abstract: Background: Regorafenib has shown substantial clinical activity in patients with advanced biliary tract cancers (BTCs). Preclinical data suggested that this drug modulates antitumour immunity and is synergistic with immune checkpoint inhibition.: ... ...

    Abstract Background: Regorafenib has shown substantial clinical activity in patients with advanced biliary tract cancers (BTCs). Preclinical data suggested that this drug modulates antitumour immunity and is synergistic with immune checkpoint inhibition.
    Patients and methods: This is a single-arm, multicentric phase II trial. Regorafenib was given 3 weeks/4, 160 mg quaque die (once a day) (QD); avelumab 10 mg/kg IV was given every two weeks, beginning at C1D15 until progression or unacceptable toxicity. The primary end-point was the confirmed objective response rate under treatment, as per Response Evaluation Criteria in Solid Tumours 1.1. The secondary end-points included the following: 1-year non-progression rate; progression-free survival (PFS) and overall survival; safety and biomarkers studies performed on sequential tumour samples obtained at baseline and at cycle 2 day 1.
    Results: Thirty-four patients were enrolled in four centres. Twenty-nine patients were assessable for efficacy after central radiological review. The best response was partial response for four patients (13.8%), stable disease for 11 patients (37.9%) and progressive disease for 14 patients (48.3%). The median PFS and overall survival were 2.5 months (95% confidence interval [CI] [1.9-5.5]) and 11.9 months (95%CI [6.2-NA]) respectively. The most common grade 3 or 4 clinical adverse events related to treatment were hypertension (17.6%), fatigue (14.7%) and maculopapular rash (11.8%). High baseline levels of programmed cell death ligand 1 and of indoleamine 2, 3-dioxygénase expression were associated with improved outcomes.
    Conclusions: Regorafenib combined with avelumab has antitumour activity in a subset of heavily pretreated biliary tract cancer population. Further investigations are needed in patients selected based on tumour microenvironment features.
    Clinical trial registration: NCT03475953.
    MeSH term(s) Antibodies, Monoclonal, Humanized/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Biliary Tract Neoplasms/drug therapy ; Humans ; Phenylurea Compounds/therapeutic use ; Pyridines/therapeutic use ; Tumor Microenvironment
    Chemical Substances Antibodies, Monoclonal, Humanized ; Phenylurea Compounds ; Pyridines ; regorafenib (24T2A1DOYB) ; avelumab (KXG2PJ551I)
    Language English
    Publishing date 2022-01-05
    Publishing country England
    Document type Clinical Trial, Phase II ; Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 82061-1
    ISSN 1879-0852 ; 0277-5379 ; 0959-8049 ; 0964-1947
    ISSN (online) 1879-0852
    ISSN 0277-5379 ; 0959-8049 ; 0964-1947
    DOI 10.1016/j.ejca.2021.11.012
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 456: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 583: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article ; Online: Trifluridine-Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer.

    Prager, Gerald W / Taieb, Julien / Fakih, Marwan / Ciardiello, Fortunato / Van Cutsem, Eric / Elez, Elena / Cruz, Felipe M / Wyrwicz, Lucjan / Stroyakovskiy, Daniil / Pápai, Zsuzsanna / Poureau, Pierre-Guillaume / Liposits, Gabor / Cremolini, Chiara / Bondarenko, Igor / Modest, Dominik P / Benhadji, Karim A / Amellal, Nadia / Leger, Catherine / Vidot, Loïck /
    Tabernero, Josep

    The New England journal of medicine

    2023  Volume 388, Issue 18, Page(s) 1657–1667

    Abstract: Background: In a previous phase 3 trial, treatment with trifluridine-tipiracil (FTD-TPI) prolonged overall survival among patients with metastatic colorectal cancer. Preliminary data from single-group and randomized phase 2 trials suggest that treatment ...

    Abstract Background: In a previous phase 3 trial, treatment with trifluridine-tipiracil (FTD-TPI) prolonged overall survival among patients with metastatic colorectal cancer. Preliminary data from single-group and randomized phase 2 trials suggest that treatment with FTD-TPI in addition to bevacizumab has the potential to extend survival.
    Methods: We randomly assigned, in a 1:1 ratio, adult patients who had received no more than two previous chemotherapy regimens for the treatment of advanced colorectal cancer to receive FTD-TPI plus bevacizumab (combination group) or FTD-TPI alone (FTD-TPI group). The primary end point was overall survival. Secondary end points were progression-free survival and safety, including the time to worsening of the Eastern Cooperative Oncology Group (ECOG) performance-status score from 0 or 1 to 2 or more (on a scale from 0 to 5, with higher scores indicating greater disability).
    Results: A total of 246 patients were assigned to each group. The median overall survival was 10.8 months in the combination group and 7.5 months in the FTD-TPI group (hazard ratio for death, 0.61; 95% confidence interval [CI], 0.49 to 0.77; P<0.001). The median progression-free survival was 5.6 months in the combination group and 2.4 months in the FTD-TPI group (hazard ratio for disease progression or death, 0.44; 95% CI, 0.36 to 0.54; P<0.001). The most common adverse events in both groups were neutropenia, nausea, and anemia. No treatment-related deaths were reported. The median time to worsening of the ECOG performance-status score from 0 or 1 to 2 or more was 9.3 months in the combination group and 6.3 months in the FTD-TPI group (hazard ratio, 0.54; 95% CI, 0.43 to 0.67).
    Conclusions: Among patients with refractory metastatic colorectal cancer, treatment with FTD-TPI plus bevacizumab resulted in longer overall survival than FTD-TPI alone. (Funded by Servier and Taiho Oncology; SUNLIGHT ClinicalTrials.gov number, NCT04737187; EudraCT number, 2020-001976-14.).
    MeSH term(s) Adult ; Humans ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Bevacizumab/adverse effects ; Bevacizumab/therapeutic use ; Colonic Neoplasms/drug therapy ; Colorectal Neoplasms/drug therapy ; Drug Combinations ; Pyrrolidines/adverse effects ; Pyrrolidines/therapeutic use ; Rectal Neoplasms/drug therapy ; Trifluridine/adverse effects ; Trifluridine/therapeutic use ; Uracil
    Chemical Substances Bevacizumab (2S9ZZM9Q9V) ; Drug Combinations ; Pyrrolidines ; tipiracil (NGO10K751P) ; Trifluridine (RMW9V5RW38) ; Uracil (56HH86ZVCT)
    Language English
    Publishing date 2023-05-03
    Publishing country United States
    Document type Journal Article ; Randomized Controlled Trial
    ZDB-ID 207154-x
    ISSN 1533-4406 ; 0028-4793
    ISSN (online) 1533-4406
    ISSN 0028-4793
    DOI 10.1056/NEJMoa2214963
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Ua VI Zs.34: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article ; Online: MiR-31-3p do not predict anti-EGFR efficacy in first-line therapy of RAS wild-type metastatic right-sided colon cancer.

    Boisteau, Emeric / Lespagnol, Alexandra / De Tayrac, Marie / Corre, Sébastien / Perrot, Anthony / Rioux-Leclercq, Nathalie / Martin-Lannerée, Séverine / Artru, Pascal / Chalabreysse, Philippe / Poureau, Pierre-Guillaume / Doucet, Laurent / Coupez, Dahna / Bennouna, Jaafar / Bossard, Céline / Coriat, Romain / Beuvon, Frédéric / Bauguion, Lucile / Leclair, François / Chautard, Romain /
    Lecomte, Thierry / Guyetant, Serge / Desgrippes, Romain / Grasset, Denis / Lhostis, Hélène / Bouhier-Leporrier, Karine / Bibeau, Frédéric / Edeline, Julien / Galibert, Marie-Dominique / Lièvre, Astrid

    Clinics and research in hepatology and gastroenterology

    2022  Volume 46, Issue 5, Page(s) 101888

    Abstract: Background: Low miR-31-3p expression was identified as predictive of anti-EGFR efficacy in RAS-wt mCRC. Primary tumor side was also proposed as a predictive factor of anti-EGFR benefit. This retrospective multicentric study evaluated the predictive role ...

    Abstract Background: Low miR-31-3p expression was identified as predictive of anti-EGFR efficacy in RAS-wt mCRC. Primary tumor side was also proposed as a predictive factor of anti-EGFR benefit. This retrospective multicentric study evaluated the predictive role of miR-31-3p in right-sided RAS-wt mCRC patients treated with first-line CT+anti-EGFR or CT+bevacizumab (Beva).
    Methods: Seventy-two right-sided RAS-wt mCRC patients treated in first-line with CT+anti-EGFR (n = 43) or Beva (n = 29) were included. Overall survival (OS), progression-free survival (PFS) and response rate (RR) were analyzed and stratified according to tumor miR-31-3p expression level and targeted therapy (TT).
    Results: BRAF V600E mutation was more frequent in high vs low miR-31-3p expressers (60.6% vs 15.4%, P < 0.001). PFS was significantly longer with CT+Beva than with CT+anti-EGFR (13 vs 7 months; P = 0.024). Among low miR-31-3p expressers, PFS, OS and RR were not significantly different between the two groups, while in high miR-31-3p expressers, only PFS was longer in the CT+Beva group (11 vs 6 months; P = 0.03). In patients treated with CT+anti-EGFR, low miR-31-3p expressers had a significantly longer OS (20 vs 13 months; P = 0.02) than high miR-31-3p expressers. ORR was not significantly different between the two groups of treatment, in both low and high miR-31-3p expressers. MiR-31-3p expression status was statistically correlated between primary tumors and corresponding metastases.
    Conclusion: In this study, miR-31-3p couldn't identify a subgroup of patients with right-sided RAS-wt mCRC who might benefit from anti-EGFR and suggest that Beva is the TT of choice in first-line treatment of these patients.
    MeSH term(s) Antineoplastic Combined Chemotherapy Protocols ; Bevacizumab/therapeutic use ; Colonic Neoplasms/drug therapy ; Colonic Neoplasms/genetics ; Colorectal Neoplasms/pathology ; ErbB Receptors/genetics ; Humans ; MicroRNAs/genetics ; Retrospective Studies
    Chemical Substances MIRN31 microRNA, human ; MicroRNAs ; Bevacizumab (2S9ZZM9Q9V) ; ErbB Receptors (EC 2.7.10.1)
    Language English
    Publishing date 2022-02-18
    Publishing country France
    Document type Journal Article
    ZDB-ID 2594333-9
    ISSN 2210-741X ; 2210-7401
    ISSN (online) 2210-741X
    ISSN 2210-7401
    DOI 10.1016/j.clinre.2022.101888
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Article ; Online: Risk factors for Coronavirus Disease 2019 (COVID-19) severity and mortality among solid cancer patients and impact of the disease on anticancer treatment

    Lièvre, Astrid / Turpin, Anthony / Ray-Coquard, Isabelle / Le Malicot, Karine / Thariat, Juliette / Ahle, Guido / Neuzillet, Cindy / Paoletti, Xavier / Bouché, Olivier / Aldabbagh, Kais / Michel, Pierre / Debieuvre, Didier / Canellas, Anthony / Wislez, Marie / Laurent, Lucie / Mabro, May / Colle, Raphael / Hardy-Bessard, Anne-Claire / Mansi, Laura /
    Colomba, Emeline / Bourhis, Jean / Gorphe, Philippe / Pointreau, Yoann / Idbaih, Ahmed / Ursu, Renata / Di Stefano, Anna Luisa / Zalcman, Gérard / Aparicio, Thomas / Moulin, Solenne / Leleu, Olivier / Leparree, Sylvie / Goasdoue, Henri / Piprot, Christine / Tourneur, Gerald / Bayart, Vincent / Lignier, Delphine / Lachaier, Emma / Khamari, Marwa / Coutte, Alexandre / Siembida, Nicolas / Houessinon, Aline / Regimbeau, Jean Marc / Chauffert, Bruno / Moreira, Aurélie / Hautefeuille, Vincent / Hee, Christine / Boone, Mathieu / Bihan, Céline / Chive, Emilie / Poulet-Potriquier, Stéphane / Fahem, Rachida / Luet, Dominique / Roquin, Guillaume / Vitellius, Carole / Cornet-Trichereau, Nathanaëlle / Caroli-Bosc, François-Xavier / Thirot-Bidault, Anne / Ropert, Stanislas / Gachet - Masson, Julie / Dehais, Mélanie / L'helgoualc'h, Gwen-Ael / Ali-Mahamadou, Ibrahim / Talfi, Safia / Belmont, Laure / Kilendo, Dieudonné / Benrezzak, Nasro / Dubief, Emeline / Conroy, Guillaume / Delique, Laurence / Basso, Maud / Pons, Isabelle / Salignon, Karine / Villing, Anne-Laure / Mougenot, Emmanuelle / Porebski, Cassandra / Guiatni, Asma / Cloarec, Nicolas / Mineur, Laurent / Bouchaud, Marie / David, Céleste / Peytier, Annie / Greletty, Thomas / Audemar, Franck / Vignes, Emanuelle / Minne, Floriane / Goldzak, Guillaume / Huysman, Fabienne / Hocine, Fayçal / Lakkis, Zaher / Meynard, Guillaume / Almotlak, Hamadi / Klajer, Elodie / Sun, Xu-Shan / Wasselin, Julie / Catala, Pascale / Mazuy, Claire / Vandamme, Hélène / Prevost, Jean-Briac / Fadin, Aurélie / Basson, Laurent / Huguet, Jean-Baptiste / Dos Santos, Emmanuelle / Jany, Bérangère / Saad, Alain / Goutorbe, Frédéric / Oziol, Eric / Ramdani, Mohamed / Kadiri, Ouafae / Garbay, Delphine / Huet, Clotilde / Giroux Leprieur, Etienne / Teng, Wen / Monvoisin, Justine / Arnaud Coffin, Patrick / Roux, Sylvie / Orfeuvre, Hubert / Chagros, Mélanie / Pillon, Didier / Rassoul, Agathe / Poureau, Pierre Guillaume / Novello, Cécile / Ducray, François / Trouba, Cécile / Bastit, Vianney / Babin, Emmanuel / Leon, Vincent / Courtecuisse, Anne-Catherine / Vambre, Julie / Tack, Vincent / Desauw, Christophe / Meniai, Fatima / Peres, Christina / Esparcieux, Aurélie / Perrier, Hervé / Doux, Nathalie / Kaphan, Régis / Roques, Bertrand / Rebischung, Christine / Mille, Dominique / Fernandes, Gaëlle / Abdelli, Naceur / Jousset, Natacha / Combe, Pierre / Jonveaux, Eric / Dumont, Patrick / Kanaan, Marc / Berthelot Gras, Corinne / Panis, Valérie / Kaluzinski, Laure / Venant-Valery, Marjolène / Lam, You-Heng / Vallee, Laura / Riviere, Frédéric / Durand, Muriel / Benghadid, Dihya / Villeneuve, Emilie / Hentic Dhome, Olivia / Bounouar, Zedjiga / De Mestier, Louis / Dubois, Jacqueline / Eyriey, Magali / Moreau, Lionel / Baihas, Dib / Aldabbagh, Kaïs / Degriffolet, Dominique / Sebbagh, Virginie / Seghezzi, Jean-Christophe / Lozach-Brugirard, Marion / Mandrou, Julie / Mavier, Loubna / Hennetier, Florence / Wagner, Jean-Philippe / Carola, Elisabeth / Chandirakumaran, Karthiga / Loutski, Sandrine / Cojean-Zelek, Isabelle / Bouras, Amina / Lacour, Sandrine / Froura, Fahem / Ben Nadji, Hadjer / Cattelain, Sophie / Darloy, Franck / Jolimoy Boilleau, Geneviève / Maissiat, Cyrielle / Darut-Jouve, Ariane / Lorgis, Véronique / Charifi-Alaoui, Ikram / Ghiringhelli, François / Drouillard, Antoine / Chaix, Marie / Manfredi, Sylvain / Lepage, Côme / Gagnaire, Alice / Latournerie, Marianne / jourdan, Sofia / Perrot, Nora / folia, Mireille / Minello, Anne / Jouve, Jean-Louis / Fery, Marielle / Landau, Alain / Evrard, Diane / Valenza, Bruno / Paitel, Jean-François / Chablais, Laetitia / Kreitmann, Thomas / Lancry-Lecomte, Laurence / Monard, Adrien / Faugeras, Eve / Boucheret, Paul / Glommeau, Cécile / Tchikladze, Christine / Garnier Tixidre, Claire / Long, Jérôme / Zaidi, Manel / Delabarre, Véronique / Meyzenc, Juliette / Ferrand, Loïc / Moro-Sibilot, Denis / Bouheret, Paul / Leyronnas, Cécile / Herve, Camille / Thoor, Audrey / Jacquet, Emanuelle / Roth, Gaël / Madapathage-Senanyake, Videsheka / Chupeau, Peggy / Bieber, Elsa / Rosso, Maud / Lepage, Isabelle / Priou, Frank / Laly, Margot / Aprelon, Sylvie / Sobolak, Natacha / Homokos, Helen / Watelle, Fabienne / Pham-Becker, Alice / Lauridant, Géraldine / Dujardin, Charlotte / Lenglin, Etienne / Nienguet Tsota, Aimée / Dominguez, Sophie / Forestier, Alexandra / Nouvel, Franck / Lerooy, Justine / Ratajczak, Céline / Romano, Olivier / Brzyski, Dorothéee / Barriere, Aurélien / Genet, Dominique / Tisse, Julien / Zasadny, Xavier / Grelet, Adeline / Hennion-Imbault, Amélie / Haustraete, Eglantine / Louafi, Samy / Awad, Manal / Zekri, Younes / Cheneau, Caroline / Leissen, Nolwen / Egreteau, Joëlle / Breant, Alexandra / Sarabi, Matthieu / Labonne, Stéphanie / Forestier, Julien / Leclercq, Céline / Prunier-Bossion, Florence / Ray Coquard, Isabelle / Guillet, Marielle / Theillaumas, Aurélie / Prome, Emilie / Walter, Thomas / Philouze, Pierre / Lawo, Melody / De Talhouet, Solène / Beuvelot, Johanne / Molin, Yann / Bellecoste Martin, Marie / Saussereau, Maud / Agnelli, Lauren / Fakhry, Nicolas / Laplace, Christophe / Norguet Monnereau, Emmanuelle / Boucard, Céline / Djenad, Kahina / Fontaine, Catherine / Seitz, Jean-François / Dahan, Laétitia / Sigrand, Julie / Duluc, Muriel / Locher, Christophe / Fleury, Marjory / Brou Marie, Ange / Berkane, Ramdane / Poupblanc, Séverine / Auby, Dominique / Petran, Daniela / Texereau, Patrick / Guerineau, Elodie / Andre, Morgan / Mahjoubi, Linda / Sarrazin, Fanny / Jeanson, Sonia / Gschwend, Anthony / Birr, Virginie / Fore, Mathieu / Noirclerc, Monique / Dahou, Sihem / Spaeth, Dominique / Lambotin, Mélanie / Lelu, Thomas / Linot, Benjamin / Hugon, Nathalie / Rousseau, Dominique / Castanie, Hélène / Lenne, Carole / Lortholary, Alain / Cessot, Anatole / Merzoug, Messaouda / Naudin, Cécile / Vannetzel, Jean-Michel / Aziz, Ghina / Hadj Arab, Yacine / Pernes, Stéphanie / Roche-Lachaise, Isabelle / Fiteni, Frédéric / Yahiaoui, Hadjer / Marel Lopez, Gwendoline / Oddoz, Jeanne / Peira, Fabienne / Michel, Olivier / Meunier, Jérôme / Ouahrani, Brahim / Roger, Antoine / Branco, Sonia / Nguyen, Van / Gisselbrecht, Mathilde / Hammad, Ghania / Mordant, Pierre / Stroksztejn, Magda / Pocard, Marc / Nlo Meyengue, Luc / Sacco, Emmanuelle / Simon Anne, Sophie / Fabre-Guillevin, Elizabeth / Slim, Marine / Zaanan, Aziz / Cadranel, Jacques / Pluvy, Johan / Ursu, Rénata / Geraldo, Amyrath / Lihi, Rime / Vo, Maryline / Brouk, Zohra / Colle, Raphaël / Bennamoun, Mostefa / Lacan, Fabrice / Louvet, Christophe / Mebarki, Soraya / Veyri, Marianne / Paillaud, Elena / Lucas, Christelle / Dubreuil, Olivier / Lyamani, Jamila / Agguini, Hanane / Soularue, Emilie / Jourdaine, Clément / Verillaud, Benjamin / Herzine, Hakima / Raymond, Eric / Mathiot, Nathalie / Palmieri, Lola Jade / Epanya, Christian / Taieb, Julien / Bertrand, Eliane / Goujon, Gaël / Namour, Céline / Gazeau, Benoit / Zafirova, Biljana / Mirghani, Haitham / Belin, Catherine / Belkhir, Kahina / Gharib, Myriam / Vozy, Aurore / Amrane, Karim / Spano, Jean-Philippe / Wassermann, Johanna / Feuvret, Loic / Bachet, Jean-Baptiste / Philonenko, Sara / Guillot, Laetitia / Zabbe, Marion / Gibiat, Stéphanie / Baylot, Camille / Jouinot, Aude / Leduc, Nicolas / Vieillot, Sabine / James, Laurie / Ducerf, Camille / Blanc, Jean-Frédéric / Falandry Leger, Claire / Wautot, Virginie / Chauvenet, Marion / Vincent, Aude / Tougeron, David / Goulvent, Sandrine / Suc, Etienne / Laurenty, Anne-Pascale / Marquis, Eric / Bonnaire, Margaux / Dewolf, Maxime / Brenet, Esteban / Billard, Delphine / Litre, Claude-Fabien / Dumazet, Antoine / Botsen, Damien / Vazel, Marion / Carlier, Claire / Bonnerave, David / Marchand-Crety, Charles / Bouche, Olivier / Fosse, Patricia / Sefrioui, David / Watson, Sarah / Torche, Fatah / Muron, Thierry / Natur, Stéphane / Desgrippes, Romain / Bihel, Véronique / Ferrand, François-Régis / Leiterer, Caroline / Lavole, Julie / Moquet, Claire / Pressoir, Nathalie / Dziukala, Catherine / Ligeza Poisson, Catherine / Naji, Abdelhalim / Williet, Nicolas / Phelip, Jean-Marc / Di Palma, Fabrice / Kherrour Mehdi, Amina / Langrand-Escure, Julien / Fournel, Pierre / Pigne, Grégoire / Saban-Roche, Léa / Magne, Nicolas / Vassal, Cécile / Jacquin, Jean-Philippe / Ramirez, Carole / Vallard, Alexis / Collard, Olivier / Rivoirard, Romain / Graber, Ivan / Trager Maury, Stéphanie / Duboisset, Elodie / Ayllon Ugarte, Jorge / Rami, Dalilia / Saler, Christine / Reinbolt, Manon / Le Fevre, Clara / Ben Abdelghani, Meher / Dourthe, Louis-Marie / Perruisseau-Carrier, Joffrey / Nguimpi-Tambou, Marlène / Barret, Flavie / Di Stefano Anna, Luisa / Balthazard, Annie / Vassord-Dang, Camille / Le Marchand, Mathilde / Vergniol, Julien / Pripon, Iulia / Daemaegdt, Axelle / Latry, Vanessa / Larrieu, Muna / Landry, Gaëlle / Touihri Maximin, Laetitia / Del Piano, Francesco / Barlet, Agnès / Vernisse, Mylène / Lafond, Sophie / Genin, Charline / Sibertin-Blanc, Camille / Chabrillac, Emilien / Gregoire, Caroline / Vergez, Sébastien / Panouille, Quentin / Guimbaud, Rosine / Richa, Floriane / Lebellec, Loïc / Gounin, Sophie / Buiret, Guillaume / Baudin, Marine / Hamon, Hervé / Deshorgue, Anne-Claire / Barrascout, Eduardo / Legrand, Stéphanie / Houlze, Morgane / Cambula, Linda / Lopez, Anthony / Fouquet, Guillaume / Touabi, Kahina / GermaIn, Adeline / Godbert, Benoit / Voivret, Florence / Perrin, Julie / Da Silva, Rosa / Bernichon, Emilie

    European Journal of Cancer

    A French nationwide cohort study (GCO-002 CACOVID-19)

    2020  Volume 141, Page(s) 62–81

    Keywords Cancer Research ; Oncology ; covid19
    Language English
    Publisher Elsevier BV
    Publishing country us
    Document type Article ; Online
    ZDB-ID 82061-1
    ISSN 1879-0852 ; 0277-5379 ; 0959-8049 ; 0964-1947
    ISSN (online) 1879-0852
    ISSN 0277-5379 ; 0959-8049 ; 0964-1947
    DOI 10.1016/j.ejca.2020.09.035
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 456: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 583: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top